Globus Medical: 7 Quarters Of Margin Expansion, Priced For None (NYSE:GMED)
· seekingalpha.com
Globus Medical is rated a buy, targeting a 17.5% return over four quarters with a constant 10.56x EV/EBITDA multiple. Click here to read this GMED stock update.
Globus Medical, Inc. ( GMED ) acquired Nevro in April 2025. As a result, every six-month comparison in the company filings mixes a quarter containing it against...